Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current Assets:    
Cash and cash equivalents $ 14,625 $ 9,954
Prepaid expenses and other current assets 1,591 2,509
Total Current Assets 16,216 12,463
Property and equipment, net 37 223
Long-term note receivable 0 700
Deposits and other assets 4 37
Total Assets 16,257 13,423
Current Liabilities:    
Accounts payable 142 395
Accrued liabilities 885 0
Total Current Liabilities 1,027 395
Total Liabilities 1,027 395
Commitments and Contingencies 0 0
Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 100,000,000 shares authorized, 58,295,808 issued and 58,214,326 outstanding and 44,444,230 issued and 44,362,748 outstanding 58 44
Additional paid-in capital 96,430 81,925
Accumulated deficit (81,258) (68,941)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 15,230 13,028
Non-controlling interest 0 0
Total Equity 15,230 13,028
Total Liabilities and Equity $ 16,257 $ 13,423